A perspective on principles of comparative cost-effectiveness studies for pharmacotherapy of chronic diseases

Clinical Diabetes

Volumn 30, Issue 2, 2012, Pages 54-60

  Farahani, Pendar ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN;

ACUTE DISEASE; ACUTE LIVER TOXICITY; ARTICLE; BIOEQUIVALENCE; CARDIOVASCULAR RISK; CHRONIC DISEASE; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MEDICAL DECISION MAKING; MYOPATHY; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; RHABDOMYOLYSIS; SECONDARY PREVENTION;

EID: 84859813577     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.30.2.54     Document Type: Article

References (75)

1. Council of State Governments: Costs of chronic diseases: what are states facing? [article online]. Available from http://www.healthystates.csg.org/NR/rdonlyres/E42141D1-4D47-4119-BFF4-A2E7FE81C698/0/Trends_Alert.pdf. Accessed 12 January 2012
2. Partnershipfor Solutions: Chronic conditions: making the case for ongoing care, September 2004 revision [article online]. Available from http://www.partnershipforsolutions. org/DMS/files/chronicbook2004.pdf. Accessed 12 January 2012
3. WorldHealth Organization: Quantifying selected major risks to health. In The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland, World Health Organization, 2002, p. 47-97
4. Cohen JD: A population-based approach to cholesterol control. Am J Med 102:23-25, 1997
5. Smith DG: Epidemiology of dyslipidemia and economic burden on the healthcare system. Am J Manag Care 13:S68-S71, 2007
6. AmericanCollege of Clinical Pharmacy: Guidelines for therapeutic interchange. Pharmacotherapy 13:252-256, 1993
7. Kendrach MG, Kelly-Freeman M: Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 38:1286-1292, 2004
8. Badia X, Russo P, Attanasio E: A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. Clin Ther 21:1788-1796, 1999
9. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH: Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 111:185-191, 2001
10. Smith DG, McBurney CR: An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Pharmacoeconomics 21 (Suppl. 1):13-23, 2003
11. Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B: Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 28:1448-1453, 2007
12. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J: High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437-2445, 2005
13. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995
14. West of Scotland Coronary Prevention Study Group: A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J Clin Epidemiol 45:849-860, 1992
15. Caro J, Klittich W, McGuire A, Ford I, Norrie J, McMurray J, Shepherd J: The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. BMJ 315:1577-1582, 1997
16. Perreault S, Levinton C, Le Lorier J: Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol 7:144-154, 2000
17. Spilker B: Guide to Clinical Trials. New York, Lippincott, Williams & Wilkins, 1991
18. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 28:1151-1157, 2005
19. Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jönsson B: Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo- Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil 12:29-36, 2005
20. Raikou M, McGuire A, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, Fuller JH: Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 50:733-740, 2007
21. Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H: Costeffectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 17:1001-1007, 1996
22. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 336:332-336, 1997
23. Perreault S, Hamilton VH, Lavoie F, Grover S: A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 10:787-794, 1997
24. Martens LL, Rutten FF, Erkelens DW, Ascoop CA: Cost effectiveness of cholesterol- lowering therapy in The Netherlands: simvastatin versus cholestyramine. Am J Med 87:54S-58S, 1989
25. Hjalte K, Lindgren B, Persson U: Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden. Pharmacoeconomics 1:213-216, 1992
26. Koren MJ, Smith DG, Hunninghake DB, Davidson MH, Weiss SR, Schrott HG, Henley RW Jr, Tresh P, McLain RW, Bakker- Arkema RG, Black DM: The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics 14:59-70, 1998
27. Linden M: Controlled clinical trials and postmarketing experience. Psychopharmakotherapie 4:26-31, 1997
28. Linden M: Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process. Psychopharmacol Bull 29:51-56, 1993
29. Farahani P, Levine M, Gaebel K, Thabane L: Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. Can J Clin Pharmacol 12:e254-e263, 2005
30. Puccetti L, Acampa M, Auteri A: Pharmacogenetics of statins therapy: recent patents. Cardiovasc Drug Discov 2:228-236, 2007
31. Mangravite LM, Krauss RM: Pharmacogenomics of statin response. Curr Opin Lipidol 18:409-414, 2007
32. Flexner C: Pharmacoecology: a new name for an old science. Clin Pharmacol Ther 83:375-379, 2008
33. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A: Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 8:iii-192, 2004
34. Farahani P, Levine M, Goeree R: A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. J Eval Clin Pract 12:463-470, 2006
35. Muls E, Van Ganse E, Closon MC: Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 137 (Suppl):S111-S116, 1998
36. Wilson K, Marriott J, Fuller S, Lacey L, Gillen D: A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. Pharmacoeconomics 21 (Suppl. 1):1-11, 2003
37. Grover SA, Coupal L, Paquet S, Zowall H: Cost-effectiveness of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 159:593-600, 1999
38. Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM: Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care 12:S412-S423, 2006
39. Grover SA, Coupal L, Lowensteyn I: Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate? Can J Cardiol 24:261-266, 2008
40. Benbassat J, Baumal R: The time horizons of formal decision analyses. Q J Med 100:383-388, 2007
41. Franco OH, Steyerberg EW, Peeters A, Bonneux L: Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention. J Epidemiol Community Health 60:839-845, 2006
42. Hilleman DE, Heineman SM, Foral PA: Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 20:819-822, 2000
43. Hirsch M, O'Donnell JC, Jones P: Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil 12:18-28, 2005
44. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW: Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 25:1035-1043, 2005
45. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155:772-779, 2008
46. Peterson AM, McGhan WF: Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 23:13-25, 2005
47. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S: Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 63:698-708, 2007
48. Cleemput I, Kesteloot K, DeGeest S: A review of the literature on the economics of noncompliance: room for methodological improvement. Health Policy 59:65-94, 2002
49. Riesen WF, Darioli R, Noll G: Lipidlowering therapy: strategies for improving compliance. Curr Med Res Opin 20:165-173, 2004
50. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED: Long-term adherence with cardiovascular drug regimens. Am Heart J 151:185-191, 2006
51. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J: Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 11:306-312, 2005
52. Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467, 2002
53. Lachaine J, Rinfret S, Merikle EP, Tarride JE: Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J 152:164-169, 2006
54. Hughes DA, Bagust A, Haycox A, Walley T: The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 10:601-615, 2001
55. McKenney JM, Davidson MH, Jacobson TA, Guyton JR: Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97:89C-94C, 2006
56. Tenenbaum A, Fisman EZ, Motro M: Rhabdomyolysis and lipid-lowering drugs. JAMA 293:1448-1449, 2005
57. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH: Statin safety: an assessment using an administrative claims database. Am J Cardiol 97:61C-68C, 2006
58. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585-2590, 2004
59. Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, Hutchinson HG: Safety of rosuvastatin. Am J Cardiol 94:882-888, 2004
60. Rosenson RS: Current overview of statin-induced myopathy. Am J Med 116:408-416, 2004
61. Newman CB, Palmer G, Silbershatz H, Szarek M: Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92:670-676, 2003
62. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR: Statin-related adverse events: a meta-analysis. Clin Ther 28:26-35, 2006
63. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 97:52C-60C, 2006
64. McAfee AT, Ming EE, Seeger JD, Quinn SG, Ng EW, Danielson JD, Cutone JA, Fox JC, Walker AM: The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 15:444-453, 2006
65. Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, Wallander MA, Johansson S: The safety of rosuvastatin in comparison with other statins in over 25 000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 17:953-961, 2008
66. Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Kjekshus J, Pyörälä K: Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 22:1771-1778, 1999
67. Cohn JN: Introduction to surrogate markers. Circulation 109:IV20-IV21, 2004
68. Aronson JK: Biomarkers and surrogate endpoints. Br J Clin Pharmacol 59:491-494, 2005
69. Olsson A, Casciano R, Stern L, Svangren P: A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. Int J Cardiol 96:51-57, 2004
70. Casciano R, Tarride JE, Breton MC, Stern L, Langer A: A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada. Can J Clin Pharmacol 11:e179-e190, 2004
71. National Institutes of Health Definitions Working Group: Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model. In Biomarkers and Surrogate Endpoints. 2nd ed. Downing GJ, Ed. Bethesda, Md., National Institutes of Health, 2000, p. 1-9
72. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH: Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 282:786-790, 1999
73. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond MG: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 276:785-791, 1996
74. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
75. CAST Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412, 1989